Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
James W Denham, Chantelle Wilcox, David Joseph, Nigel A Spry, David S Lamb, Keen-Hun Tai, John Matthews, Chris Atkinson, Sandra Turner, David Christie, Nirdosh Kumar Gogna, Lizbeth Kenny, Gillian Duchesne, Brett Delahunt, Patrick McElduff
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2012
National Health and Medical Research Council of Australia, Novartis Pharmaceuticals Australia, Abbott Pharmaceuticals Australia, New Zealand Health Research Council, New Zealand Cancer Society, University of Newcastle (Australia), Hunter Medical Research Institute, Calvary Mater Radiation Oncology Fund, and Maitland Cancer Appeal.This study was funded by the National Health and Medical Research Council (Canberra, ACT, Australia), Novartis Pharmaceuticals, Abbott Pharmaceuticals (both Sydney, NSW, Australia), New Zealand Health Research Council, New Zealand Cancer Society, University of Newcastle (Australia), Hunter Medical Research Institute (New Lambton Heights, NSW, Australia), Calvary Mater Radiation Oncology Fund (Waratah, NSW, Australia), and Maitland Cancer Appeal (Rutherford, NSW, Australia). We thank Madeleine King (Psycho-oncology Co-operative Research Group, University of Sydney, NSW, Australia) for her expert advice regarding interpretation of clinically important differences in quality-of-life outcomes; and Rosemary Bradford (Prostate Cancer Trials Group, University of Newcastle) for her skilful preparation of the report.